Simon J. Stanworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simon J. Stanworth has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Angela Casbard
Centre for Trials Research, Cardiff University, Cardiff, UK
1 shared publication Brian McClelland
Scottish National Blood Service
1 shared publicationC. Dyer
Department of Haematology, John Radcliffe Hospital, Headington, Oxford, UK
1 shared publicationC.J. Hyde
1 shared publication- Carolyn Doree
Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK
1 shared publication - Charlotte Bennett
Neonatal Unit, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 6 December 2012
- Published by Springer Nature
A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies
- 6 December 2012
- Published by Springer Nature
Open AccessA randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies
- 1 November 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 124 (5) , e826-e834
Prospective, Observational Study of Outcomes in Neonates With Severe Thrombocytopenia
OBJECTIVE: A cross-sectional, observational study of outcomes for neonates with severe neonatal thrombocytopenia (SNT; platelet count of 9 platelets per L) was performed to examine hemorrhage and use of platelet transfusions. METHODS: Neonates who were admitted to 7 NICUs and developed SNT were enrolled for daily data collection. RESULTS: Among 3652 neonatal admissions, 194 neonates (5%) developed SNT. The median gestational age of 169 enrolled neonates was 27 weeks (interquartile range [IQR]: 24–32 weeks), and the median birth weight was 822 g (IQR: 670–1300 g). Platelet count nadirs were 9, 20 to 39 × 109, and 40 to 59 × 109 platelets per L for 58 (34%), 64 (39%), and 47 (28%) of all enrolled infants, respectively. During the study, 31 infants (18%) had no recorded hemorrhage, 123 (73%) developed minor hemorrhage, and 15 (9%) developed major hemorrhage. Thirteen (87%) of 15 episodes of major hemorrhage occurred in neonates with gestational ages of n = 415) were administered to 116 infants (69%); for 338 (81%) transfusions, the main recorded reason was low platelet count. Transfusions increased the platelet count from a median of 27 × 109 platelets per L (IQR: 19–36 × 109 platelets per L) to 79 × 109 platelets per L (IQR: 47.5–127 × 109 platelets per L). CONCLUSIONS: Although one third of neonates enrolled in this study developed thrombocytopenia of 9 platelets per L, 91% did not develop major hemorrhage. Most platelet transfusions were given to neonates with thrombocytopenia with no bleeding or minor bleeding only.
- 1 November 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 124 (5) , e826-e834
Prospective, Observational Study of Outcomes in Neonates With Severe Thrombocytopenia
OBJECTIVE: A cross-sectional, observational study of outcomes for neonates with severe neonatal thrombocytopenia (SNT; platelet count of 9 platelets per L) was performed to examine hemorrhage and use of platelet transfusions. METHODS: Neonates who were admitted to 7 NICUs and developed SNT were enrolled for daily data collection. RESULTS: Among 3652 neonatal admissions, 194 neonates (5%) developed SNT. The median gestational age of 169 enrolled neonates was 27 weeks (interquartile range [IQR]: 24–32 weeks), and the median birth weight was 822 g (IQR: 670–1300 g). Platelet count nadirs were 9, 20 to 39 × 109, and 40 to 59 × 109 platelets per L for 58 (34%), 64 (39%), and 47 (28%) of all enrolled infants, respectively. During the study, 31 infants (18%) had no recorded hemorrhage, 123 (73%) developed minor hemorrhage, and 15 (9%) developed major hemorrhage. Thirteen (87%) of 15 episodes of major hemorrhage occurred in neonates with gestational ages of n = 415) were administered to 116 infants (69%); for 338 (81%) transfusions, the main recorded reason was low platelet count. Transfusions increased the platelet count from a median of 27 × 109 platelets per L (IQR: 19–36 × 109 platelets per L) to 79 × 109 platelets per L (IQR: 47.5–127 × 109 platelets per L). CONCLUSIONS: Although one third of neonates enrolled in this study developed thrombocytopenia of 9 platelets per L, 91% did not develop major hemorrhage. Most platelet transfusions were given to neonates with thrombocytopenia with no bleeding or minor bleeding only.
- 31 August 2008
- Published by Elsevier in Early Human Development
- Vol. 84 (8) , 507-513
How to tackle bleeding and thrombosis in the newborn
- 31 August 2008
- Published by Elsevier in Early Human Development
- Vol. 84 (8) , 507-513
How to tackle bleeding and thrombosis in the newborn
- 1 December 2007
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 14 (6) , 551-556
Evidence for indications of fresh frozen plasma
- 1 December 2007
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 14 (6) , 551-556
Evidence for indications of fresh frozen plasma
- Open Access
- 1 January 2007
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2007 (1) , 179-186
The Evidence-Based Use of FFP and Cryoprecipitate for Abnormalities of Coagulation Tests and Clinical Coagulopathy
There continues to be a general but unfounded enthusiasm for fresh frozen plasma (FFP) or frozen plasma (FP) usage across a range of clinical specialties in hospital practice. Plasma for transfusion is most often used where there are abnormal coagulation screening tests, either therapeutically in the face of bleeding, or prophylactically in nonbleeding patients prior to invasive procedures or surgery. Little evidence exists to inform best therapeutic transfusion practice, and most studies describe plasma use in a prophylactic setting. Laboratory abnormalities of coagulation are considered by many clinicians to be a predictive risk factor for bleeding prior to invasive procedures or in other clinical situations where bleeding risk exists, and plasma for transfusion is presumed to improve the laboratory results and reduce this risk. However, most guideline indications for the prophylactic use of plasma for transfusion are not supported by evidence from good-quality randomized trials. Arguably, the strongest randomized controlled trial (RCT) evidence indicates that prophylactic plasma for transfusion is not effective across a range of different clinical settings, and this is supported by data from nonrandomized studies in patients with mild to moderate abnormalities in coagulation tests. There is a need to undertake new trials evaluating the efficacy and adverse effects of plasma, both in bleeding and non-bleeding patients, to understand whether the presumed benefits outweigh the real risks. In addition, new hemostatic tests that better define the risk of bleeding and monitor the effectiveness of the use of FFP should be validated. Last, there is an opportunity to develop effective educational strategies aimed at addressing understanding and compliance with recommendations in guidelines.
- 1 January 2007
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2007 (1) , 179-186
Open AccessThe Evidence-Based Use of FFP and Cryoprecipitate for Abnormalities of Coagulation Tests and Clinical Coagulopathy
There continues to be a general but unfounded enthusiasm for fresh frozen plasma (FFP) or frozen plasma (FP) usage across a range of clinical specialties in hospital practice. Plasma for transfusion is most often used where there are abnormal coagulation screening tests, either therapeutically in the face of bleeding, or prophylactically in nonbleeding patients prior to invasive procedures or surgery. Little evidence exists to inform best therapeutic transfusion practice, and most studies describe plasma use in a prophylactic setting. Laboratory abnormalities of coagulation are considered by many clinicians to be a predictive risk factor for bleeding prior to invasive procedures or in other clinical situations where bleeding risk exists, and plasma for transfusion is presumed to improve the laboratory results and reduce this risk. However, most guideline indications for the prophylactic use of plasma for transfusion are not supported by evidence from good-quality randomized trials. Arguably, the strongest randomized controlled trial (RCT) evidence indicates that prophylactic plasma for transfusion is not effective across a range of different clinical settings, and this is supported by data from nonrandomized studies in patients with mild to moderate abnormalities in coagulation tests. There is a need to undertake new trials evaluating the efficacy and adverse effects of plasma, both in bleeding and non-bleeding patients, to understand whether the presumed benefits outweigh the real risks. In addition, new hemostatic tests that better define the risk of bleeding and monitor the effectiveness of the use of FFP should be validated. Last, there is an opportunity to develop effective educational strategies aimed at addressing understanding and compliance with recommendations in guidelines.
- 8 May 2006
- Published by Wiley in Vox Sanguinis
- Vol. 91 (1) , 63-69
Feasibility and usefulness of self‐assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding
Background and Objectives The aim of this study was to evaluate the collection of daily prospective information about bleeding outcomes in patients with thrombocytopenia, including information obtained by patient self‐assessment.Materials and Methods Consecutive patients with haematological malignancies were enrolled in a study of bleeding data collection during the period of thrombocytopenia. A short educational session and information sheet was designed for self‐assessment. Platelet counts and all transfusions were recorded daily. Bleeding scores were translated into World Health Organization (WHO) bleeding grades.Results Nineteen patients were included in the study. Four‐hundred and ten days of thrombocytopenia were eligible for assessment of bleeds. Self‐assessment was feasible, as defined by the total proportion of days on which self‐assessment was completed (70%, 288 thrombocytopenic days). There was 86% agreement between bleeding data collected by self‐assessment and by medical examination using a structured assessment form. Examples of discrepancies included the duration of petechiae/bruises and the reporting of minor bleeding. There was no evidence for an association between patients’ morning platelet count and daily WHO bleeding grade. The incidences of WHO grade 1 and grade 2 bleeding on days with platelet counts ≤ 10 × 109/l, 11–20 × 109/l, and > 20 × 109/l were similar and did not reveal higher rates of bleeding at lower counts.Conclusions Patient self‐assessment can help to support comprehensive daily prospective monitoring of bleeding, specifically facilitating data collection following hospital discharge. The discrepancies between self‐assessment and medical examination highlight the need to develop a validated international assessment tool. The association among platelet count, risk of bleeding and role of prophylactic platelet transfusions needs further evaluation in larger prospective trials.
- 8 May 2006
- Published by Wiley in Vox Sanguinis
- Vol. 91 (1) , 63-69
Feasibility and usefulness of self‐assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding
Background and Objectives The aim of this study was to evaluate the collection of daily prospective information about bleeding outcomes in patients with thrombocytopenia, including information obtained by patient self‐assessment.Materials and Methods Consecutive patients with haematological malignancies were enrolled in a study of bleeding data collection during the period of thrombocytopenia. A short educational session and information sheet was designed for self‐assessment. Platelet counts and all transfusions were recorded daily. Bleeding scores were translated into World Health Organization (WHO) bleeding grades.Results Nineteen patients were included in the study. Four‐hundred and ten days of thrombocytopenia were eligible for assessment of bleeds. Self‐assessment was feasible, as defined by the total proportion of days on which self‐assessment was completed (70%, 288 thrombocytopenic days). There was 86% agreement between bleeding data collected by self‐assessment and by medical examination using a structured assessment form. Examples of discrepancies included the duration of petechiae/bruises and the reporting of minor bleeding. There was no evidence for an association between patients’ morning platelet count and daily WHO bleeding grade. The incidences of WHO grade 1 and grade 2 bleeding on days with platelet counts ≤ 10 × 109/l, 11–20 × 109/l, and > 20 × 109/l were similar and did not reveal higher rates of bleeding at lower counts.Conclusions Patient self‐assessment can help to support comprehensive daily prospective monitoring of bleeding, specifically facilitating data collection following hospital discharge. The discrepancies between self‐assessment and medical examination highlight the need to develop a validated international assessment tool. The association among platelet count, risk of bleeding and role of prophylactic platelet transfusions needs further evaluation in larger prospective trials.
- 18 October 2004
- Published by Wiley
- No. 4,p. CD004269
Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation
Background Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 30 years, some areas continue to provoke debate especially the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding. Objectives To determine the optimal use of platelet transfusion for the prevention of haemorrhage (prophylactic platelet transfusion) in patients with haematological malignancies undergoing chemotherapy or stem cell transplantation. Search methods Randomised controlled trials (RCTs) were searched for in the Cochrane Central Register of Controlled Trials (CENTRAL). Searching was also undertaken on the OVID versions of MEDLINE and EMBASE using an RCT search filter strategy. Selection criteria Randomised controlled trials involving transfusions of platelet concentrates, prepared either from individual units of whole blood or by apheresis, and given prophylactically to prevent bleeding in patients with haematological malignancies. Data collection and analysis All electronically derived citations and abstracts of papers, identified by the review search strategy, were initially screened for relevancy by one reviewer. The full text of all potentially relevant trials was then formally assessed for eligibility by two reviewers independently. Two reviewers completed data extraction independently. Missing data were requested from the original investigators, as appropriate. Main results Eight completed published trials, with a total of 390 participants in the intervention groups and 362 participants in the control groups, were included for analysis in the review. The eight studies were classified as: three trials relevant to prophylactic platelet transfusions versus therapeutic platelet transfusions; three trials relevant to prophylactic platelet transfusion with one trigger level versus prophylactic platelet transfusion with another trigger level; two trials relevant to prophylactic platelet transfusion with one dose schedule versus prophylactic platelet transfusion with another dose schedule. The few reports of controlled trials addressing prophylactic versus therapeutic transfusions contained small numbers of patients and were all undertaken over 25 years ago. None of the studies explicitly clarified whether the lack of a reported difference was a reflection of insufficient power in the trials. The findings of the meta‐analyses for this group of three small studies must be interpreted with caution. In contrast, more contemporary trials addressed the question of what platelet count thresholds should apply for prophylactic transfusion; three identified studies broadly compared platelet transfusion thresholds of 10 versus 20 x 109/litre for different clinical groups of patients. There were no statistically significant differences between the groups with regards to mortality, remission rates, number of participants with severe bleeding events or red cell transfusion requirements. However, it was unclear whether the studies had sufficient power to demonstrate in combination non‐inferiority in terms of safety of the lower threshold, 10x109/litre. Insufficient randomised trials have been undertaken to make clinically relevant conclusions about the effect of different platelet doses. Authors' conclusions There are no reasons to change current practice, but uncertainty about the practice of prophylactic transfusion therapy should be recognised, particularly in the light of concerns about the scenario that blood products including platelets could become an increasingly scarce resource in the future and for which adequate alternatives do not exist. Consideration should be given to developing adequately powered trials comparing strategies of prophylaxis versus therapeutic platelet transfusion.
- 18 October 2004
- Published by Wiley
- No. 4,p. CD004269
Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation
Background Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 30 years, some areas continue to provoke debate especially the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding. Objectives To determine the optimal use of platelet transfusion for the prevention of haemorrhage (prophylactic platelet transfusion) in patients with haematological malignancies undergoing chemotherapy or stem cell transplantation. Search methods Randomised controlled trials (RCTs) were searched for in the Cochrane Central Register of Controlled Trials (CENTRAL). Searching was also undertaken on the OVID versions of MEDLINE and EMBASE using an RCT search filter strategy. Selection criteria Randomised controlled trials involving transfusions of platelet concentrates, prepared either from individual units of whole blood or by apheresis, and given prophylactically to prevent bleeding in patients with haematological malignancies. Data collection and analysis All electronically derived citations and abstracts of papers, identified by the review search strategy, were initially screened for relevancy by one reviewer. The full text of all potentially relevant trials was then formally assessed for eligibility by two reviewers independently. Two reviewers completed data extraction independently. Missing data were requested from the original investigators, as appropriate. Main results Eight completed published trials, with a total of 390 participants in the intervention groups and 362 participants in the control groups, were included for analysis in the review. The eight studies were classified as: three trials relevant to prophylactic platelet transfusions versus therapeutic platelet transfusions; three trials relevant to prophylactic platelet transfusion with one trigger level versus prophylactic platelet transfusion with another trigger level; two trials relevant to prophylactic platelet transfusion with one dose schedule versus prophylactic platelet transfusion with another dose schedule. The few reports of controlled trials addressing prophylactic versus therapeutic transfusions contained small numbers of patients and were all undertaken over 25 years ago. None of the studies explicitly clarified whether the lack of a reported difference was a reflection of insufficient power in the trials. The findings of the meta‐analyses for this group of three small studies must be interpreted with caution. In contrast, more contemporary trials addressed the question of what platelet count thresholds should apply for prophylactic transfusion; three identified studies broadly compared platelet transfusion thresholds of 10 versus 20 x 109/litre for different clinical groups of patients. There were no statistically significant differences between the groups with regards to mortality, remission rates, number of participants with severe bleeding events or red cell transfusion requirements. However, it was unclear whether the studies had sufficient power to demonstrate in combination non‐inferiority in terms of safety of the lower threshold, 10x109/litre. Insufficient randomised trials have been undertaken to make clinically relevant conclusions about the effect of different platelet doses. Authors' conclusions There are no reasons to change current practice, but uncertainty about the practice of prophylactic transfusion therapy should be recognised, particularly in the light of concerns about the scenario that blood products including platelets could become an increasingly scarce resource in the future and for which adequate alternatives do not exist. Consideration should be given to developing adequately powered trials comparing strategies of prophylaxis versus therapeutic platelet transfusion.
- 20 October 2003
- Published by Wiley
- No. 4
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
- 20 October 2003
- Published by Wiley
- No. 4
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia